Computer aided R&D to revolutionize pharmaceutical products and applications
Drug Design & Discovery
Medicinal Chemistry design
Prediction Tools for Drug Development
Toxicity - Ecotoxicity
Predictions of interactions with gut microflora
New Product Development
Biomarkers of efficacy, tolerance
In vitro ADMET
In vitro efficacy
Nanocarriers and delivery
Cloudpharm is a bio-pharmaceutical R&D Company founded and established in Greece in 2016. Its core business focuses on the discovery of bioactive compounds and next generation food supplements. Cloudpharm develops state-of-the-art algorithms for drug repurposing and provides computational services for drug design and development.
Using our proprietary technology and latest computational methodologies, coupled with our scientific expertise in the field of drug discovery and health product development, a wide network of industrial and academic collaborators, we aim to deliver integrated solutions to the pharmaceutical industry.
We believe in creating value. Cloudpharm is a flexible and versatile R&D partner to every pharmaceutical company that wants to implement next generation methodologies for the development of new products.
Meet the team
Business Development, Biochemist & Biotechnologist MSc
Scientific Project Manager, Material Engineer MSc
R&D Scientist, Biomedical Engineer MSc
Scientific Project Manager, Chemical Engineer PhD
National Hellenic Research Foundation
University of West Attica
Autonomous University of Barcelona
TTMI Consulting Ltd
Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact (ENVIROMED)
The EU-funded ENVIROMED project aims at reducing the overall environmental impact of pharmaceuticals via: a) reducing the environmental footprint of the manufacturing processes, and b) better understanding of the environmental impact of pharmaceuticals.
CLOUDPHARM is associated with the project’s Work Packages WP1, WP2, WP3, WP6 and WP8. CLOUDPHARM’s research approach will be implemented through three research work packages (WP2, WP3 and WP6) by being in charge of developing novel in-silico tools for “green-by-design” pharmaceuticals, along with predicting the ecotoxicity impact of pharmaceuticals using in silico methods.
Development of a one-stop-shop drug repositioning platform (Cloudscreen)
The goal of this project is the development of a new generation “one stop shop” platform (CloudScreen). In the present work, 1D data (genomic-transcriptomic-proteomic-metabolomic) and text services (patents, ethical and legal issues) will be integrated with 3D data (computational chemistry, molecular design), analyzed and interpreted with a minimum of manual processing, combining the reasoning skills of artificial and human intelligence. The system, in addition, will be updated dynamically, promoting cost-effectiveness. The resulting 3D map of proteins and protein variants/proteoforms will empower efficacy and toxicity prediction, evaluation, and validation for the repurposed drugs. The second goal of the project is the validation of the generated platform through a pilot application in the drug market to ensure the governance and trust of the CloudScreen work environment.
Design and development of a novel food supplement for osteoporosis based on gut microbiome mechanisms (OSTEOME)
OSTEOME aspires to design and develop a novel dietary supplement for osteoporosis, activating the intestinal microbiome. At the same time companion biomarkers will be studied related to the efficacy and tolerability of the new supplement. The selection of flavonoids will take place through in vitro and in silico studies focusing on their interaction with pathways that regulate the activity of osteoclasts and osteoblasts. The efficacy and tolerability of the dietary supplement will be evaluated through a randomized clinical intervention. OSTEOME brings together a team with complementary expertise and technical know-how including three research entities and two SMEs.
Next Generation Food Supplements (NextGFS)
The aim of the project is to implement a new methodological approach which will guide the design of a new generation of nutritional supplements. Specific objectives for the project are:
(A) the development of a platform for designing nutritional supplements through computational tools.
(B) the pilot production of a new dietary supplement with anti-inflammatory and antioxidant properties, aiming primarily at patients with osteoarthritis (OA).
(C) the implementation of a clinical trial using the new dietary supplement on volunteers with OA.
Next Generation Training on Intelligent Greenhouses (NEGHTRA)
NEGHTRA is a specialized training project that addresses knowledge transfer in precision agriculture based on specific needs and challenges, identified from a comprehensive need analysis. It aims to provide innovative training on smart greenhouse technologies coupled with selected optimum matchings of technologies/cultivations with regions including conditions for economic and environmental sustainability. Also, this project aims at the development of an adaptable and flexible lifelong learning system, ensuring high quality and efficient teaching. It aspires the delivery of knowledge to farmers of how innovation, entrepreneurship and technology utilization can benefit their businesses, personal skills and competence development.
Cloudpharm is one of the 5 Greek startups entering the final phase of Pfizer’s Start4Health Challenge.
Our drug repurposing computational platform Cloudscreen, adopts next gen algorithms for drug repurposing and provides AI powered predictions towards novel indications for existing drugs, coupled with state-of-the-art validation tools. Cloudscreen is currently being...
We are very excited to announce the partnership with Cosmos Holdings (NASDAQ:COSM), to develop new products targeting the gut microbiome. Our mission is closely aligned with Cosmos, as they are devoted to developing new and innovative products using high-quality...
Cloudpharm announces the approval of the funded project “Cloudscreen” in collaboration with the Institute of Chemical Biology of the National Hellenic Research Foundation (NHRF). The objective of the project is the development of a next generation “one-stop-shop”...
Cloudpharm announces the approval of the funded project “OSTEOME” in collaboration with the Musculoskeletal Diseases Research Laboratory “Th. Garofalidis ”of the Medical School of EKPA, the Institute of Chemical Biology of the National Research Foundation (NHRF),...
In this editorial, we argue for a holistic view of evidence-based practices via the synergy of human and artificial intelligence in drug discovery. This strategy may build a collaborative conceptual framework to enable better-informed and rapid decisions, and the...
In this work, Cloupharm has been involved in the discovery of four compounds through a virtual screening procedure as putative sterol 14α-demethylase (CYP51) Candida albicans inhibitors. The compounds had the ability to inhibit growth of C. albicans cells and one...